We wi yɛri di wɔd kansa, bɔku pan wi kin fred ɛn wi kin fil bad. Dat na nɔmal tin. Bɔt we di sayɛns bɔt mɛrɛsin dɔn go bifo, nyu tritmɛnt dɛn dɔn kam na di wɔl we de ɛp wi fɔ kɔntrol kansa ɛn liv bɛtɛ layf. Tide, wi go tɔk bɔt wan rili spɛshal klas fɔ drɔgs we de tɔch ɛn stɔp di kansa sɛl dɛn we de gro. Dɛn kɔl dɛn tin ya Tyrosine Kinase Inhibitors, ɔ TKI fɔ shɔt tɛm.
Fɔ tɔk am simpul wan, wetin na Tyrosine Kinase Inhibitors (TKI)?
Dis na wan kayn mɛrɛsin wae dɛn kɔl "targeted therapies." Tink bɔt dis we: fɔ mɛn kansa ɔltɛm (kimotɛrapi) tan lɛk bɔm we dɛn kin drɔp na wɔ. I kin kil ɛnimi sojaman dɛn (kansa sɛl dɛn) ɛn bak wi yon pipul dɛn we nɔ du natin (sɛl dɛn we gɛt wɛlbɔdi). Bɔt dis tritmɛnt we dɛn de tɔk to we dɛn kɔl TKI tan lɛk snaypa. I de luk di rayt tin we i want fɔ du ɛn i de pwɛl di kansa sɛl dɛn nɔmɔ. Di damej we de pan di sɛl dɛn we gɛt wɛlbɔdi nɔ bɔku.
Dɛn mɛrɛsin ya de wok bay we dɛn de blok di ɛnzaym dɛn we de insay di kansa sɛl dɛn we de ɛp dɛn fɔ gro ɛn sheb kwik kwik wan. Dɛn mɛrɛsin ya nɔr kin mɛn kansa kpatakpata, bɔt dɛn kin ɛp fɔ kɔntrol di kansa ɛn put am na lɔng tɛm rɛmishɔn , ɔr kin ɛp yu fɔ liv lɔng ɛn wɛl bɔdi wit di kansa.
Aw dis mɛrɛsin de wok insay di bɔdi?
Fɔ ɔndastand dis, lɛ wi luk aw di sɛl dɛn na wi bɔdi de kɔntrol. Tink bɔt we wi sɛl dɛn de sheb lɛk se wi de ɔn layt.
1. Di tin dɛn we de mek pɔsin gro: Dɛn tin ya tan lɛk di finga we de flip di layt switch. na dεn de gi di sεl dεm di signal fכ "divayd naw."
2. Tyrosine kinases: Dis na di layt swich dεm. We yu flik dɛn wit yu finga, dɛn kin tɔn ‘On’, ɛn di sɛl dɛn kin bigin fɔ sheb. We di nid nɔ de igen, dɛn kin tɔn ‘Off’ bak.
Insay sɛl dɛn we gɛt wɛlbɔdi, dis swich de wok fayn fayn wan. I de tɔn ‘On’ we nid de, ɛn i de tɔn ‘Off’ we di wok dɔn.
Bɔt insay sɔm kansa sɛl dɛn, mɔ na wan kayn blɔd kansa we dɛn kɔl Chronic Myeloid Leukemia (CML) , dis swich we dɛn kɔl ‘Tyrosine kinase’ kin brok. Na ‘On’ de ɔltɛm. dat min se di sεl dεm de gεt di signal כltεm fכ "divayd, divayd, divayd." So dɛn kansa sɛl dɛn ya kin sheb we dɛn nɔ ebul fɔ kɔntrol, ɛn dɛn kin ful-ɔp di bon mɛrɔ ɛn stɔp fɔ mek blɔd sɛl dɛn we gɛt wɛlbɔdi.
Na da tɛm de TKI drɔgs kin kam insay. Wetin dɛn drɔgs ya de du na fɔ fos fɔ ɔf da switch we dɔn brok ɛn we de on ɔltɛm. Dɔn di kansa sɛl dɛn kin lɔs di sayn fɔ sheb, ɛn dɛn kin stɔp fɔ gro. Yu ɔndastand aw da prɔses de spɛshal?
Us kayn kansa dɛn kin yuz TKI drɔgs fɔ?
Naw dɛn de yuz dɛn mɛrɛsin ya fɔ bɔku kayn kansa. Si di tebul we de dɔŋ ya.
| Tayp fɔ Kansa | Wan simpul ɛksplen |
|---|---|
| HER2-positiv brɔst kansa | wan kayn brεst kεnsar we gεt εksyכs pan wan protin we dεn kכl HER2 na di sεl dεm. |
| Kronik limfosaytik lukimiya | Wan blɔd kansa we de gro sloslo we kin afɛkt wan kayn wayt blɔd sɛl. |
| Gastrointestinal stromal tכmכro dεm | Na wan kayn kansa we nɔ kin apin so ɔltɛm we kin apin na di wɔl dɛn na di dijestiv sistɛm. |
| Kidni kansa | Fɔ kansa dɛm we kin bigin na di sɛl dɛm na di kidni dɛm. |
| Lɔng kansa (Nɔn-smɔl sɛl lɔng kansa) . | Fɔ trit di kayn kansa wae kin kam pan pɔrsin na in lɔng. |
| Kansa na di skin (Melanoma) . | Wan siriɔs kayn kansa na di skin we kin kam na di sɛl dɛn we de gi di skin in kɔlɔ. |
Di impɔtant tin na dat nɔto ɔl TKI drɔgs de wok fɔ ɔl kayn kansa. Yu dɔktɔ go pik di rayt mɛrɛsin fɔ yu bay di jenɛtik mek-ap fɔ yu kansa.
Ɛni bad tin de we dɛn mɛrɛsin ya kin du?
Yɛs. Lɛk ɛni mɛrɛsin, dis wan kin gɛt sayd ɛfɛkt. Bɔt dɛn tin ya kin difrɛn bad bad wan frɔm wan pɔsin to ɔda pɔsin ɛn i kin difrɛn frɔm di kayn mɛrɛsin we yu de tek. Sɔm pipul dɛn kin gɛt smɔl prɔblɛm nɔmɔ, ɛn ɔda wan dɛn kin gɛt mɔ bad bad tin.
Sɔm pan di sayd ɛfɛkt dɛm we dɛn kin si na:
- Taya ɛn taya: Dis kin rili kɔmɔn.
- Daya: Di bɔdi we de kɔmɔt na di bɔdi.
- Prɔblɛm dɛn na di skin: Skin de rɔsh, dray, it, ɛn ɔda tin dɛn.In rare cases , siriɔs skin kɔndishɔn lɛk Stevens-Johnson syndrome kin apin.
- Nɔs ɛn vɔmit
- Ay blɔd prɛshɔn (haypa prɛshɔn) .
- Proteinuria we dɛn kin yuz
- We yu de lɔs ɔ we yu de gɛt mɔ wet
Impɔtant: Bifo yu bigin dis tritmɛnt, yu dɔktɔ go tɔk klia wan bɔt di sayd ɛfɛkt dɛn we di mɛrɛsin we yu go de tek go gɛt. I rili impɔtant fɔ tɛl yu dɔktɔ wantɛm wantɛm if yu gɛt ɛni nyu sayn ɔr yu nɔr fil fayn we yu de trit yu.
Wetin wi go du fɔ mek i izi fɔ wi fɔ trit am?
Tritmɛnt fɔ kansa na wan tranga waka, pan ɔl we yu bɔdi ɛn maynd. Sɔm tin dɛn de we yu kin du fɔ mek dis waka izi smɔl.
- Di bɛst tin fɔ taya na fɔ rɛst: If yu fil taya, ɔndastand se na nɔmal tin. Gɛt bɔku rɛst as yu ebul. I fayn bak fɔ slip smɔl insay di de.
- Tek tɛm wit di tin dɛn we yu de it: Sɔm pipul dɛn kin lɔs dɛn wet bikɔs dɛn nɔ kin want fɔ it. Ɔda wan dɛn kin gɛt mɔ wet. If yu fil dis kayn we, aks fɔ ɛp frɔm pɔsin we sabi bɔt it . Dɔn dɛn kin mek wan it plan we go fit yu sityueshɔn.
- Plan yu de: Di tritmɛnt kin chenj yu ɛvride layf bɔku bɔku wan. Tray fɔ ɔganayz tin bay we yu mak yu dɔktɔ apɔntinmɛnt ɛn mɛrɛsin apɔntinmɛnt na kalenda.
- Lan bɔt Palliative Care: Dis na tin wae bɔrku pipul nɔr no bɔt, bɔt i rili impɔtant. Palliative care na spɛshal kayn kia wae, apat frɔm di tritmɛnt fɔ kansa, de ɛp yu fɔ liv fayn fayn wan wit yu sik bay wae yu de kɔntrol di sayn dɛm lɛk pen, nɔs, taya, ɛn di sayd ɛfɛkt dɛm wae yu gɛt fɔ tritmɛnt. Aks yu dɔktɔ bɔt dis.
As tɛm de go, sɔm kansa sɛl dɛn kin ebul fɔ bia wit dɛn TKI drɔgs ya ɛn stɔp fɔ ansa to tritmɛnt. Dɛn kɔl dis ‘drug resistance’. Dɛn kayn tɛm ya, yu dɔktɔ kin chenj yu to difrɛn TKI mɛrɛsin ɔ difrɛn tritmɛnt we dɛn kin gi yu. So, i rili impɔtant fɔ de kɔntakt yu dɔktɔ ɔltɛm we yu de trit yu.
Mɛsej we dɛn kin kɛr go na os
- Tyrosine Kinase Inhibitors (TKI) na wan klas fכ advans dכg dεm we de tכk εn blכk di signal sistεm we de involv fכ gro fכ di kεnsar sεl dεm.
- Bifo dɛn tin ya kin mɛn kansa kpatakpata, dɛn kin kɔntrol di sik ɛn ɛp di wan dɛn we sik fɔ liv lɔng ɛn bɛtɛ layf.
- Bɔku tɛm dɛn kin gi dis tritmɛnt as pil we dɛn kin tek ɛvride, ɛn na yu dɔktɔ kin disayd di tritmɛnt plan.
- Di sayd ɛfɛkt dɛn kin apin ɛn dɛn kin difrɛn frɔm wan pɔsin to ɔda pɔsin. I impɔtant fɔ tɔk to yu dɔktɔ wantɛm wantɛm bɔt ɛnitin we nɔ izi fɔ yu.
- TKI drɔgs na big big tin fɔ mɛn kansa, we de gi nyu op to bɔku pasɛnt dɛn.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt